This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: EAS Academy

Themed Short Track: How can we improve outcomes in our patients with CAD?

Wednesday 9 September 2020   (0 Comments)
Share |

Introducing Themed Short Tracks

In SHORT TRACKS we collect 2-4 recent lectures from EAS congresses or courses, putting them together to provide up-to-date perspectives on a given current topic.

This month’s Short Track topic is: How can we improve outcomes in our patients with CAD?

This is a CME Educational Programme held at the 87th EAS Congress in Maastricht. The programme included three lectures. An introductory presentation discussed the current situation of LDL-cholesterol (LDL-C) control in Europe, the second lecture was focused on the optimal lipid-lowering therapies and the third lecture discussed new methods to improve adherence to recommended lifestyle and therapies, that could lead to the improvement of outcomes in cardiovascular disease patients.

                 To the SHORT TRACK How can we improve outcomes in our patients with CAD? >>

These presentations are Open Access for members and non-members.

What is the price to pay if we are not at goal?

This presentation was given by Professor Alberto Zambon who is the Director of the Lipoprotein Core Laboratory at the Centre for Atherosclerosis Prevention and Treatment, Department of Medicine, University of Padua, Italy.
In his excellent overview, Professor Zambon discussed the current situation of LDL-C control in Europe, focused on patients with established cardiovascular disease (CVD) and on those with calcuated score greater that 10% (subjects with very high risk without established CVD).

He presented results form primary prevention studies emphasizing that upto 50% of this high or very high risk population were not on any lipid lowering medication and only 1 out of ten were at target for LDL-C. He further presented the results of secondary prevention studies, emphasizing that although most of patients were on statin therapy, only 1 out of 3 achieved the LDL-C goals. Professor Zambon discussed the high event rates these patients have over a 10-years period, suggesting that there is a definite extreme price to pay by not considering the proper level of LDL-C. Finally, he noticed that the direct and indirect health care costs attributable to CVD are expected to substantially increase. 

Optimal lipid lowering therapy: New and established therapies

The 2nd presentation was given by Professor Christie Ballantyne, from the Center for Cardiomertabolic Disease Prevention, Baylor College of Medicine at Houston, Texas.
In his very comprehensive lecture, Professor Ballantyne presented data from clinical trials on the effectiveness of lipid lowering drugs in reducing the major vascular events by decreasing the LDL-C levels.


He started his lecture presenting data from statin trials and subsequently he briefly discussed the results from clinical trials on other lipid lowering drugs (ezetimibe, PCSK9 inhibitors, bempedoic acid) used either as monotherapy or in combination with a statin. He concluded that there is overwhelming evidence for the benefit of statin monotherapy or the combination of a statin with another lipid lowering drug, in the reduction of cardiovascular events proportionally to the absolute LDL-C reduction. However, he noticed that implementation in clinical practice, lags far behind guidelines. 

Optimal lipid lowering therapy: New and established therapies


The 3rd presentation was given by Professor Lale Tokgözoğlu, Professor of Cardiology at the Hacettepe University of Ankara, Turkey, and President of the European Atherosclerosis Society.
Professor Tokgözoğlu started her excellent presentation reporting that cardiovascular mortality has significantly decreased in the past few decades due to improved risk factor management.

However, there is a potential for much more reduction. Importantly she noticed that the great scientific progress made and the benefits of existing effective therapies observed in randomized-controlled trials, do not always translate into real life, because the patients are older, sicker and have more comorbidities, but mostly because the patients do not adhere to the recommended lifestyle and therapies. Professor Tokgözoğlu further presented data from clinical trials on the low patients’ adherence to recommended therapies and discussed the major determinants of this non adherence. Finally, she proposed several approaches (including the use of new technologies) that could help in modifying patients’ behaviour and increasing their adherence to the recommended in guidelines lifestyle and therapies that could lead to the improvement of patients’ outcomes.

Membership Software Powered by YourMembership  ::  Legal